FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281746258> ?p ?o ?g. }

• W4281746258 endingPage "TPS7069" @default.
• W4281746258 startingPage "TPS7069" @default.
• W4281746258 abstract "TPS7069 Background: Fosciclopirox (F) is a γ-secretase inhibitor being developed for the treatment of acute myeloid leukemia (AML). Following intravenous (IV) administration, F is rapidly and completely metabolized to its active metabolite, ciclopirox (CPX). CPX binds to γ-secretase complex proteins Presenilin 1 and Nicastrin, which are essential for Notch activation. In HL60 cells, CPX inhibits Notch 1 and Notch 2 expression, reduces levels of γ-secretase complex proteins Presenilin 1 and Nicastrin, and decreases expression of the downstream Notch target gene Hes-1. Utilizing Notable Labs predictive precision medicine platform, bone marrow (BM) and peripheral blood (PB) samples obtained from 10 AML patients treated with CPX demonstrated significant blast count reductions. Methods: Study CPX-POM-003 (NCT04956042) is an open-label Phase 1B/2A, trial designed to characterize the efficacy, safety, and PK/PD of F alone and in combination with cytarabine (ara-C) in patients with relapsed/refractory AML (R/R AML). Eligible patients must be 18 years of age or older with relapsed AML after complete remission or with primary refractory AML refractory to at least two cycles of induction therapy. There will be up to three cohorts of patients, approximately 42 R/R AML patients, evaluated. If disease response to F alone (Cohort 1a) is observed in at least 4 of 14 patients, an additional 14 patients will be enrolled in Cohort 1b. If disease response is not observed following F alone, the study may be terminated or a second cohort, Cohort 2a, may be initiated to evaluate the combination of F + ara-C. If disease response to F + ara-C is observed in at least 4 of 14 patients, an additional 14 patients will be enrolled in Cohort 2b. If response to F + ara-C is not observed in at least 4 of 14 patients, the study will be stopped for futility. F is being administered as 900 mg/m 2 once daily as a 20-minute IV infusion on Days 1 to 5 of each 21-day treatment cycle. Ara-C is administered as 1 gm/m 2 once daily on Days 1 to 5 of each cycle. BM and PB samples are collected prior to and during Cycles 1 (C1) and 2 (C2) for disease response assessment and blast count determination. Additional BM and PB samples are obtained after every two cycles beyond C2 for patients continuing treatment. Disease response is determined based on Döhner et al, Blood 2017;129(4)424-447. Next Generation Sequencing (NGS) profiles will be determined prior to and at the end of C1, and thereafter as clinically indicated. Immunohistochemistry will be performed on BM samples to elucidate drug mechanism. Ex vivo Drug Sensitivity Screening (DSS) will be performed on BM and PB samples obtained prior to treatment as well as on C1 Days 8 and 21. The steady-state plasma pharmacokinetics of F are being characterized during C1. Enrollment began in October 2022 with four patients enrolled to date. Clinical trial information: NCT04956042." @default.
• W4281746258 created "2022-06-13" @default.
• W4281746258 creator A5002299630 @default.
• W4281746258 creator A5006831611 @default.
• W4281746258 creator A5007538471 @default.
• W4281746258 creator A5016314692 @default.
• W4281746258 creator A5018712784 @default.
• W4281746258 creator A5024030506 @default.
• W4281746258 creator A5027320590 @default.
• W4281746258 creator A5035236340 @default.
• W4281746258 creator A5035668092 @default.
• W4281746258 creator A5041349401 @default.
• W4281746258 creator A5042467158 @default.
• W4281746258 creator A5053022132 @default.
• W4281746258 creator A5059984287 @default.
• W4281746258 creator A5060461293 @default.
• W4281746258 creator A5069406381 @default.
• W4281746258 creator A5074378503 @default.
• W4281746258 creator A5081641853 @default.
• W4281746258 creator A5086797465 @default.
• W4281746258 creator A5087011324 @default.
• W4281746258 creator A5087699643 @default.
• W4281746258 date "2022-06-01" @default.
• W4281746258 modified "2023-10-18" @default.
• W4281746258 title "Phase 1B/2A safety, pharmacokinetics, and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia." @default.
• W4281746258 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.tps7069" @default.
• W4281746258 hasPublicationYear "2022" @default.
• W4281746258 type Work @default.
• W4281746258 citedByCount "0" @default.
• W4281746258 crossrefType "journal-article" @default.
• W4281746258 hasAuthorship W4281746258A5002299630 @default.
• W4281746258 hasAuthorship W4281746258A5006831611 @default.
• W4281746258 hasAuthorship W4281746258A5007538471 @default.
• W4281746258 hasAuthorship W4281746258A5016314692 @default.
• W4281746258 hasAuthorship W4281746258A5018712784 @default.
• W4281746258 hasAuthorship W4281746258A5024030506 @default.
• W4281746258 hasAuthorship W4281746258A5027320590 @default.
• W4281746258 hasAuthorship W4281746258A5035236340 @default.
• W4281746258 hasAuthorship W4281746258A5035668092 @default.
• W4281746258 hasAuthorship W4281746258A5041349401 @default.
• W4281746258 hasAuthorship W4281746258A5042467158 @default.
• W4281746258 hasAuthorship W4281746258A5053022132 @default.
• W4281746258 hasAuthorship W4281746258A5059984287 @default.
• W4281746258 hasAuthorship W4281746258A5060461293 @default.
• W4281746258 hasAuthorship W4281746258A5069406381 @default.
• W4281746258 hasAuthorship W4281746258A5074378503 @default.
• W4281746258 hasAuthorship W4281746258A5081641853 @default.
• W4281746258 hasAuthorship W4281746258A5086797465 @default.
• W4281746258 hasAuthorship W4281746258A5087011324 @default.
• W4281746258 hasAuthorship W4281746258A5087699643 @default.
• W4281746258 hasConcept C111113717 @default.
• W4281746258 hasConcept C112705442 @default.
• W4281746258 hasConcept C121332964 @default.
• W4281746258 hasConcept C126322002 @default.
• W4281746258 hasConcept C142424586 @default.
• W4281746258 hasConcept C143998085 @default.
• W4281746258 hasConcept C2778041864 @default.
• W4281746258 hasConcept C2778729363 @default.
• W4281746258 hasConcept C71924100 @default.
• W4281746258 hasConcept C72563966 @default.
• W4281746258 hasConcept C87355193 @default.
• W4281746258 hasConcept C90924648 @default.
• W4281746258 hasConcept C98274493 @default.
• W4281746258 hasConceptScore W4281746258C111113717 @default.
• W4281746258 hasConceptScore W4281746258C112705442 @default.
• W4281746258 hasConceptScore W4281746258C121332964 @default.
• W4281746258 hasConceptScore W4281746258C126322002 @default.
• W4281746258 hasConceptScore W4281746258C142424586 @default.
• W4281746258 hasConceptScore W4281746258C143998085 @default.
• W4281746258 hasConceptScore W4281746258C2778041864 @default.
• W4281746258 hasConceptScore W4281746258C2778729363 @default.
• W4281746258 hasConceptScore W4281746258C71924100 @default.
• W4281746258 hasConceptScore W4281746258C72563966 @default.
• W4281746258 hasConceptScore W4281746258C87355193 @default.
• W4281746258 hasConceptScore W4281746258C90924648 @default.
• W4281746258 hasConceptScore W4281746258C98274493 @default.
• W4281746258 hasIssue "16_suppl" @default.
• W4281746258 hasLocation W42817462581 @default.
• W4281746258 hasOpenAccess W4281746258 @default.
• W4281746258 hasPrimaryLocation W42817462581 @default.
• W4281746258 hasRelatedWork W1983994230 @default.
• W4281746258 hasRelatedWork W2170932148 @default.
• W4281746258 hasRelatedWork W2353568056 @default.
• W4281746258 hasRelatedWork W2370782339 @default.
• W4281746258 hasRelatedWork W2808444974 @default.
• W4281746258 hasRelatedWork W2889610980 @default.
• W4281746258 hasRelatedWork W2946223770 @default.
• W4281746258 hasRelatedWork W3032260332 @default.
• W4281746258 hasRelatedWork W4213318772 @default.
• W4281746258 hasRelatedWork W4243347672 @default.
• W4281746258 hasVolume "40" @default.
• W4281746258 isParatext "false" @default.
• W4281746258 isRetracted "false" @default.
• W4281746258 workType "article" @default.